Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has a beta value of 1.07 and has seen 1,263,891 shares traded in the last trading session. The company, currently valued at $326.5 Million, closed the last trade at $11.09 per share which meant it lost -$1.57 on the day or -12.4% during that session. The BCLI stock price is -22.72% off its 52-week high price of $13.61 and 69.07% above the 52-week low of $3.43. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.45 Million shares traded. The 3-month trading volume is 594.74 Million shares.

The consensus among analysts is that Brainstorm Cell Therapeutics Inc. (BCLI) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.26.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) trade information

Despite being -12.4% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the BCLI stock price touched $13.61- or saw a rise of 18.52%. Year-to-date, Brainstorm Cell Therapeutics Inc. shares have moved 159.11%, while the 5-day performance has seen it change 15.52%. Over the past 30 days, the shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) have changed 48.86%. Short interest in the company has seen 3.16 Million shares shorted with days to cover at 0.01.

Brainstorm Cell Therapeutics Inc. (BCLI) estimates and forecasts

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -9.4% over the past 5 years. Earnings growth for 2020 is a modest -52.2% while over the next 5 years, the company’s earnings are expected to increase by 0%.